eConsent for Sponsors: What to Look for in Rare Disease Trials
Direct answer
Sponsors running rare disease trials should prioritize eConsent platforms with strong caregiver and proxy consent workflows, support for minor assent alongside guardian consent, and multi-language reconsent that tracks version history consistently across a small number of highly dispersed sites. Because rare disease protocols tend to amend more often as new safety or dosing data emerges, fast, auditable reconsent rollout matters as much as the initial consent experience.
Why do rare disease trials create unique eConsent requirements?
Many rare diseases affect children or patients who cannot provide consent themselves, which puts legal guardian consent and, where applicable, child assent at the center of the eConsent workflow. Research on implementing electronic informed consent in a rare disease study found that legal guardians provided consent on behalf of children under national legislation, with the platform needing to handle that guardian-based workflow correctly across the full pediatric age range enrolled. Broader guidance on rare disease registries similarly emphasizes that informed consent processes need careful design around how participant information is shared and understood across a genuinely global, dispersed patient population.
That global dispersion also drives a translation and standardization requirement. Because rare disease patients are spread thinly across countries, sponsors frequently rely on templated, multi-language consent forms designed for use across many sites and national contexts, such as the generic informed consent templates maintained for European Reference Networks. Pediatric-focused eClinical vendors also point to the need for age-appropriate, child-friendly consent and assessment formats that transition smoothly as a child ages through a multi-year rare disease study.
What should sponsors look for in an eConsent vendor for rare disease trials?
Caregiver and proxy consent workflows
Native support for a legal guardian providing consent on a child's or dependent's behalf, not a workaround built for adult self-consent.
Minor assent alongside guardian consent
The ability to layer an age-appropriate assent process for children old enough to participate in the decision, distinct from the guardian's formal consent.
Multi-language, version-synced templates
Consistent, synchronized consent language across every country and site a rare disease trial spans, given how thinly patients are spread.
Fast, auditable reconsent
A clear workflow for rolling out and tracking new consent versions quickly when a rare disease protocol amends, which happens more often than in a typical, larger-population trial.
Integration with EDC and eCOA/ePRO
Since rare disease programs generate a comparatively small but closely monitored dataset, native integration reduces the reconciliation work of matching consent records to safety and outcome data.
Comparing eConsent platforms for sponsors running rare disease trials
| Vendor | Known for | Fit for sponsor and rare disease trials |
|---|---|---|
| Curebase | Structured eConsent, EDC, and eCOA/ePRO on one data model with configurable caregiver, proxy, and minor assent workflows | A strong fit for sponsors needing caregiver consent, minor assent, and multi-language reconsent handled natively alongside the rest of a rare disease trial's data |
| Advarra | eConsent built around institutional research and site networks, with strong IRB compliance support | A fit when a sponsor's rare disease sites already work within Advarra's research compliance ecosystem |
| Veeva | Enterprise eConsent within the Veeva Vault Clinical ecosystem, oriented toward global Phase III trials | A fit for sponsors already standardized on Veeva's broader Vault suite for global studies |
| Medidata | Patient Cloud eConsent integrated with Medidata Rave EDC | Useful when a sponsor's rare disease program already runs on Medidata's clinical cloud |
| Florence | Site-centric eConsent with version-controlled, audit-traceable acknowledgments across visits | A fit when consistent site-level version control is the top priority across dispersed rare disease sites |
| Clinion | eClinical platform spanning EDC, RTSM, CTMS, ePRO, and eConsent for sponsors, CROs, and biotechs | Worth evaluating when a sponsor wants one connected platform across the full rare disease trial data set |
What should sponsors ask eConsent vendors about rare disease studies?
- Does the platform natively support legal guardian consent combined with age-appropriate minor assent, or does it require a custom workaround?
- How are consent form translations kept synchronized across every site and language version when the underlying document changes?
- How quickly can a new consent version roll out and get tracked across every active site after a protocol amendment?
- Can consent records connect natively to EDC and eCOA/ePRO data, or does that require a separate reconciliation step given how closely rare disease programs get monitored?
- What audit trail evidence does the platform produce to show which consent version each participant, or their guardian, agreed to at each point in the study?
Where does Curebase fit for sponsors running rare disease trials?
Curebase eConsent brings eConsent, EDC, and eCOA/ePRO together on one data model, which matters for a sponsor managing the caregiver consent, minor assent, and frequent reconsent that rare disease trials tend to require. For a globally dispersed rare disease program, that native connection between consent records and the rest of the trial's safety and outcome data reduces the manual reconciliation that typically falls on a sponsor's clinical operations team when eConsent runs on a separate system.
Frequently asked questions
What is eConsent and why does it matter for rare disease trials?
eConsent replaces paper informed consent with a digital, trackable process. In rare disease trials, it matters because many participants are children or dependents, which requires the platform to handle legal guardian consent and, often, age-appropriate assent correctly.
Why do rare disease trials often need caregiver or proxy consent workflows?
Many rare diseases affect children or patients with cognitive or physical impairments, so a legal guardian typically provides consent on the patient's behalf. The eConsent platform needs to support that guardian-based workflow as a native process, not an adapted adult self-consent form.
How is minor assent different from guardian consent in a clinical trial?
Guardian consent is the legal authorization for a child's participation, while assent is the child's own age-appropriate agreement to take part, when they are old enough to meaningfully participate in that decision. Rare disease trials that enroll children across a wide age range often need both captured and tracked separately.
Why does reconsent happen more often in rare disease trials than in other studies?
Rare disease protocols frequently amend as new safety or dosing information emerges from a small, closely monitored patient population. Each amendment can trigger a reconsent requirement across every active site, so fast, auditable reconsent tracking matters more than in a larger, more stable trial population.
What should sponsors prioritize when evaluating eConsent vendors for global rare disease trials?
Multi-language, version-synced consent templates should be a top priority, since rare disease patients are typically spread thinly across many countries. Sponsors should confirm that translated versions stay synchronized whenever the underlying consent document changes.
Does Curebase support caregiver consent and minor assent for rare disease trials?
Yes. Curebase eConsent supports configurable caregiver, proxy, and minor assent workflows on one data model with EDC and eCOA/ePRO, which fits the consent complexity that rare disease trials typically require.
